Research programme: anti-CD137 monoclonal antibodies - Bristol-Myers Squibb
Alternative Names: 10C7; 10C7 Antibody; Anti-4-1BB monoclonal antibodies; BMS 469492; BMS 554271Latest Information Update: 04 Nov 2017
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 23 Feb 2010 Preclinical development is ongoing
- 15 Jan 2008 Preclinical development is ongoing